急性呼吸窘迫综合征
肺炎
脂多糖
下调和上调
医学
间充质干细胞
肺
全身给药
免疫学
免疫疗法
免疫系统
急性呼吸窘迫
药理学
癌症研究
化学
生物
内科学
病理
体内
生物化学
生物技术
基因
作者
Yi Wu,Heng Wang,Anning Song,Xiaoyu Wang,Qingle Ma,Chenlu Yao,Jialu Xu,Huaxing Dai,Chao Wang,Ting Lu,Xu Fang
出处
期刊:ACS Biomaterials Science & Engineering
[American Chemical Society]
日期:2023-10-16
卷期号:9 (11): 6464-6471
被引量:1
标识
DOI:10.1021/acsbiomaterials.3c01173
摘要
Acute respiratory distress syndrome (ARDS) is a severe lung condition with a high mortality rate and a lack of effective drug therapy. In this work, we developed mesenchymal stem cell (MSC)-derived extracellular vesicles with high PD-L1 expression (MSC-EVs-PD-L1) for treating lipopolysaccharide (LPS)-induced pneumonia by intratracheal administration. We found an upregulation of PD-1 expression in the inflammatory region of murine lungs; hence, MSC-EVs-PD-L1 exerted immunosuppressive effects via the PD-1/PD-L1 signaling pathway. Furthermore, we treated LPS-induced pneumonia mice by intratracheal administration, which enabled heavy drug accumulation in the lungs of mice and better therapeutic efficacy compared to systemic administration. Our results suggest that MSC-EVs-PD-L1 has the potential to provide a universal platform technology for the immunotherapy of pneumonia.
科研通智能强力驱动
Strongly Powered by AbleSci AI